Tasigna — CareFirst (Caremark)
Tenosynovial Giant Cell Tumor (TGCT)
Initial criteria
- Requested for treatment of PVNS or TGCT as a single agent
Reauthorization criteria
- No evidence of unacceptable toxicity or disease progression while on the current regimen
Approval duration
Initial and continuation 12 months